These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10632065)

  • 1. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors.
    Gupta SP; Babu MS
    Bioorg Med Chem; 1999 Nov; 7(11):2549-53. PubMed ID: 10632065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors.
    Gupta SP; Babu MS; Garg R; Sowmya S
    J Enzyme Inhib; 1998 Sep; 13(6):399-407. PubMed ID: 9825304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.
    Avram S; Bologa C; Flonta ML
    J Mol Model; 2005 Mar; 11(2):105-15. PubMed ID: 15714296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
    Garg R; Bhhatarai B
    Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
    Patel M; Rodgers JD; McHugh RJ; Johnson BL; Cordova BC; Klabe RM; Bacheler LT; Erickson-Viitanen S; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3217-20. PubMed ID: 10576691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
    Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
    Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.
    Yadav D; Paliwal S; Yadav R; Pal M; Pandey A
    PLoS One; 2012; 7(11):e48942. PubMed ID: 23145032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
    J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
    Takashiro E; Watanabe T; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Nishigaki T; Shibayama T; Nakagawa A; Iwamoto A; Yabe Y
    Bioorg Med Chem; 1998 May; 6(5):595-604. PubMed ID: 9629473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors.
    Schaal W; Karlsson A; Ahlsén G; Lindberg J; Andersson HO; Danielson UH; Classon B; Unge T; Samuelsson B; Hultén J; Hallberg A; Karlén A
    J Med Chem; 2001 Jan; 44(2):155-69. PubMed ID: 11170625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
    Kazmierski WM; Andrews W; Furfine E; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5689-92. PubMed ID: 15482949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.